Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 53

1.

C-Raf inhibits MAPK activation and transformation by B-Raf(V600E).

Karreth FA, DeNicola GM, Winter SP, Tuveson DA.

Mol Cell. 2009 Nov 13;36(3):477-86. doi: 10.1016/j.molcel.2009.10.017.

2.

A dimerization-dependent mechanism drives RAF catalytic activation.

Rajakulendran T, Sahmi M, Lefrançois M, Sicheri F, Therrien M.

Nature. 2009 Sep 24;461(7263):542-5. doi: 10.1038/nature08314. Epub 2009 Sep 2.

PMID:
19727074
3.

Ras/MAPK signaling from endomembranes.

Fehrenbacher N, Bar-Sagi D, Philips M.

Mol Oncol. 2009 Aug;3(4):297-307. doi: 10.1016/j.molonc.2009.06.004. Epub 2009 Jun 26. Review.

4.

Emerging biological functions of the vaccinia-related kinase (VRK) family.

Klerkx EP, Lazo PA, Askjaer P.

Histol Histopathol. 2009 Jun;24(6):749-59. doi: 10.14670/HH-24.749. Review.

PMID:
19337973
5.

Positive- and negative-feedback regulations coordinate the dynamic behavior of the Ras-Raf-MEK-ERK signal transduction pathway.

Shin SY, Rath O, Choo SM, Fee F, McFerran B, Kolch W, Cho KH.

J Cell Sci. 2009 Feb 1;122(Pt 3):425-35. doi: 10.1242/jcs.036319.

6.

Thyroid hormone receptor beta1 acts as a potent suppressor of tumor invasiveness and metastasis.

Martínez-Iglesias O, Garcia-Silva S, Tenbaum SP, Regadera J, Larcher F, Paramio JM, Vennström B, Aranda A.

Cancer Res. 2009 Jan 15;69(2):501-9. doi: 10.1158/0008-5472.CAN-08-2198.

7.

Ras subcellular localization defines extracellular signal-regulated kinase 1 and 2 substrate specificity through distinct utilization of scaffold proteins.

Casar B, Arozarena I, Sanz-Moreno V, Pinto A, Agudo-Ibáñez L, Marais R, Lewis RE, Berciano MT, Crespo P.

Mol Cell Biol. 2009 Mar;29(5):1338-53. doi: 10.1128/MCB.01359-08. Epub 2008 Dec 29.

8.

Targeted therapies in breast cancer: where are we now?

Di Cosimo S, Baselga J.

Eur J Cancer. 2008 Dec;44(18):2781-90. doi: 10.1016/j.ejca.2008.09.026. Epub 2008 Nov 14. Review.

PMID:
19013786
9.

K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

Karapetis CS, Khambata-Ford S, Jonker DJ, O'Callaghan CJ, Tu D, Tebbutt NC, Simes RJ, Chalchal H, Shapiro JD, Robitaille S, Price TJ, Shepherd L, Au HJ, Langer C, Moore MJ, Zalcberg JR.

N Engl J Med. 2008 Oct 23;359(17):1757-65. doi: 10.1056/NEJMoa0804385.

10.

Annexin A6 inhibits Ras signalling in breast cancer cells.

Vilá de Muga S, Timpson P, Cubells L, Evans R, Hayes TE, Rentero C, Hegemann A, Reverter M, Leschner J, Pol A, Tebar F, Daly RJ, Enrich C, Grewal T.

Oncogene. 2009 Jan 22;28(3):363-77. doi: 10.1038/onc.2008.386. Epub 2008 Oct 13.

PMID:
18850003
11.

EGFR family: structure physiology signalling and therapeutic targets.

Burgess AW.

Growth Factors. 2008 Oct;26(5):263-74. doi: 10.1080/08977190802312844. Review.

PMID:
18800267
12.

Prognostic breast cancer signature identified from 3D culture model accurately predicts clinical outcome across independent datasets.

Martin KJ, Patrick DR, Bissell MJ, Fournier MV.

PLoS One. 2008 Aug 20;3(8):e2994. doi: 10.1371/journal.pone.0002994.

13.

VRK1 phosphorylates CREB and mediates CCND1 expression.

Kang TH, Park DY, Kim W, Kim KT.

J Cell Sci. 2008 Sep 15;121(Pt 18):3035-41. doi: 10.1242/jcs.026757. Epub 2008 Aug 19.

14.

The functional interaction of 14-3-3 proteins with the ERK1/2 scaffold KSR1 occurs in an isoform-specific manner.

Jagemann LR, Pérez-Rivas LG, Ruiz EJ, Ranea JA, Sánchez-Jiménez F, Nebreda AR, Alba E, Lozano J.

J Biol Chem. 2008 Jun 20;283(25):17450-62. doi: 10.1074/jbc.M709185200. Epub 2008 Apr 21.

15.

IMP modulates KSR1-dependent multivalent complex formation to specify ERK1/2 pathway activation and response thresholds.

Chen C, Lewis RE, White MA.

J Biol Chem. 2008 May 9;283(19):12789-96. doi: 10.1074/jbc.M709305200. Epub 2008 Mar 10.

16.

Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer.

Amado RG, Wolf M, Peeters M, Van Cutsem E, Siena S, Freeman DJ, Juan T, Sikorski R, Suggs S, Radinsky R, Patterson SD, Chang DD.

J Clin Oncol. 2008 Apr 1;26(10):1626-34. doi: 10.1200/JCO.2007.14.7116. Epub 2008 Mar 3.

17.

Modulation of interleukin-1 transcriptional response by the interaction between VRK2 and the JIP1 scaffold protein.

Blanco S, Sanz-García M, Santos CR, Lazo PA.

PLoS One. 2008 Feb 20;3(2):e1660. doi: 10.1371/journal.pone.0001660.

18.

Human VRK1 is an early response gene and its loss causes a block in cell cycle progression.

Valbuena A, López-Sánchez I, Lazo PA.

PLoS One. 2008 Feb 20;3(2):e1642. doi: 10.1371/journal.pone.0001642.

19.

Vaccinia-related kinase 2 modulates the stress response to hypoxia mediated by TAK1.

Blanco S, Santos C, Lazo PA.

Mol Cell Biol. 2007 Oct;27(20):7273-83. Epub 2007 Aug 20.

20.

Alteration of the VRK1-p53 autoregulatory loop in human lung carcinomas.

Valbuena A, Suárez-Gauthier A, López-Rios F, López-Encuentra A, Blanco S, Fernández PL, Sánchez-Céspedes M, Lazo PA.

Lung Cancer. 2007 Dec;58(3):303-9. Epub 2007 Aug 8.

PMID:
17689819

Supplemental Content

Support Center